※SOSEI：「A2A拮抗薬の将来性」- BioCenturyがそーせいのAZD4635の記事(Reprint From 2018/3/26)を掲載。併用療法の後期第I相／第II相試験データは2021年になる見込みである。(5/16)
※ClinicalTrials: Phase 1b/2, MEDI9447 EGFRm NSCLC Novel Combination Study (MEDI9447 with Osimertinib or AZD4635, AZD4635 with MEDI9447). "Recruiting", Actual Study Start: "2018/5/8" (5/16update)
※Sunovion: present eight posters featuring data from treatments for COPD at ATS 2018. New data analyses include three posters reporting effects of Seebri and Utibron on lung function and patient-reported outcomes. (5/16)
※四季報業績予想(2018/5/11更新)：2018.12予(変) 売上高6,500百万円、営業利益-1,500百万円、税前利益-1,500百万円、純利益-1,300百万円、1株益-17.1円。(5/16up)
※RCSB Protein Data Bank: (Structure ID: 6GDG): "Cryo-EM structure of the adenosine A2A receptor bound to a miniGs heterotrimer": (Released: 2018/5/16) (5/16up)
・・・
Events
※World Advanced Therapies & Regenerative Medicine Congress 2018: "Placental derived cell for allogeneic treatment of solid cancer": Zami Aberman, Pluristem. (Today 15:10)
※ASGCT: "Short Activating RNAs. MTL-CEBPa has a Broad Range of Liver Disease Models and Encouraging Early Clinical Data in a Phase 1 Trial in HCC": Nagy Habib, MiNA Therapeutics. (5/18 9:00)
※AstraZeneca Q1 2018 Results and Annual General Meeting: (5/18)